Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Analysts

Shares of Omeros Co. (NASDAQ:OMER) have received an average rating of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.50.

A number of equities research analysts recently commented on OMER shares. Rodman & Renshaw initiated coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday, December 19th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th.

Hedge Funds Weigh In On Omeros

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its position in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares in the last quarter. MML Investors Services LLC grew its stake in shares of Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 3,000 shares during the last quarter. SPC Financial Inc. bought a new position in shares of Omeros during the third quarter valued at $77,000. SG Americas Securities LLC purchased a new position in shares of Omeros in the 3rd quarter worth about $80,000. Finally, AQR Capital Management LLC bought a new position in Omeros in the 2nd quarter worth about $105,000. Institutional investors own 48.79% of the company’s stock.

Omeros Price Performance

OMER opened at $11.68 on Monday. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The stock’s 50 day simple moving average is $7.73 and its 200 day simple moving average is $5.43. The firm has a market cap of $676.86 million, a price-to-earnings ratio of -5.06 and a beta of 1.97.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.